Prostaglandin E2 and Regulation of Kidney Function
Prostaglandin E2 and Regulation of Kidney Function
批准号:
8540409
负责人:
THOMAS M COFFMAN
金额:
$30.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-02-07 至 2015-07-31
关键词:
AffectAngiotensin IIAttenuatedBlood PressureBlood VesselsCardiovascular systemCellsDevelopmentDinoprostoneDistalDrug or chemical Tissue DistributionDuct (organ) structureEP4 receptorEndotheliumExcretory functionExperimental ModelsFamilyFundingGene TargetingGenerationsGeneticGoalsHormonesHypertensionHypotensionIndividualJuxtaglomerular ApparatusKidneyLaboratoriesLinkMacula densaMediatingMolecularMusNatriuresisNephronsPathogenesisPathway interactionsPatternPeripheralPopulationProductionProstaglandinsProtein IsoformsPublic HealthReceptor ActivationRegulationRenal TissueRenal functionReninRenin-Angiotensin SystemResistanceRoleSeveritiesSignal PathwaySiteSmooth Muscle MyocytesTechniquesTestingTherapeuticTissuesTransplantationUnited StatesVascular Endothelial CellVascular EndotheliumVascular resistanceVasoconstrictor AgentsVasodilationVasopressinsWaterWorkbaseblood pressure regulationdefined contributionefficacy testinghypertension treatmentin vivoinsightmouse modelnew therapeutic targetnovelprostanoid receptor EP1public health relevancereceptorreceptor functionresearch studyresponsesolutetherapeutic targeturinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Among the prostanoids, PGE2 is unique in that its actions are mediated by a family of four different E- prostanoid (EP) receptor isoforms. These receptors (EP1-4) have distinct tissue distributions and couple to disparate signaling pathways, providing a molecular basis for the range of functions attributed to PGE2 in the kidney and in other tissues. Thus, the impact of PGE2 generation on blood pressure may differ depending on its sites of synthesis and the resulting pattern of EP receptor activation. For example, we showed that the EP4 receptor is primarily responsible for triggering expression of renin at the juxtaglomerular apparatus (JGA) via the macula densa pathway. Furthermore, our preliminary studies using two novel mouse models show that: (1) cell-specific deletion of EP4 receptors in endothelium attenuates vasoconstrictor responses to angiotensin II and (2) generalized elimination of EP4 receptors confers substantial resistance to angiotensin II-dependent hypertension. Taken together, these findings suggest a consistent function for the EP4 receptor to promote increased blood pressure through independent mechanisms that include activating the RAS, promoting hypertensive effects of angiotensin II, and enhancing peripheral vascular resistance. The objective of the studies proposed here is to precisely define mechanisms linked to the EP4 receptor that may contribute to the pathogenesis of hypertension. Specifically, we will use genetically modified mouse models and EP4 receptor antagonists to provide new insights into the role of EP4 receptors in cardiovascular regulation. To this end, we will pursue the following Specific Aims: (1) To determine the specific role of EP4 receptors in the kidney in the pathogenesis of hypertension. (2) To establish the impact of EP4 receptor pools in the endothelium and vascular smooth muscle cells (VSMCs) on blood pressure control. (3) To define the contribution of EP4 receptors in the collecting duct to the regulation of blood pressure and renal excretory function. (4) To test the potential of the EP4 receptor as a therapeutic target in hypertension. The long-term goal of these experiments is to determine the potential of the EP4 receptor as a novel therapeutic target in hypertension.
PUBLIC HEALTH RELEVANCE:
High blood pressure is a major public health problem in the United States affecting more than 50 million individuals. Our proposal explores a novel pathway promoting the development of hypertension: activation of the EP4 receptor for prostaglandin E2. We will explore the mechanism used by the EP4 receptor to raise blood pressure and will define its potential utility as a therapeutic target for the treatment of hypertension.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
Paracrine Control of Blood Pressure by Renal Intercalated Cells
-
批准号:9070607
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2015
-
负责人:THOMAS M COFFMAN
-
依托单位:
Administrative Core
-
批准号:8433280
-
项目类别:
-
资助金额:$18.05万
-
财政年份:2012
-
负责人:THOMAS M COFFMAN
-
依托单位:
George M. O'Brien Kidney Research Core Centers
-
批准号:8385010
-
项目类别:
-
资助金额:$115.72万
-
财政年份:2012
-
负责人:THOMAS M COFFMAN
-
依托单位:
George M. O'Brien Kidney Research Core Centers
-
批准号:8912150
-
项目类别:
-
资助金额:$3.02万
-
财政年份:2012
-
负责人:THOMAS M COFFMAN
-
依托单位:
George M. O'Brien Kidney Research Core Centers
-
批准号:8529521
-
项目类别:
-
资助金额:$116.23万
-
财政年份:2012
-
负责人:THOMAS M COFFMAN
-
依托单位:
Genetic Determinants of Susceptibility to Kidney Disease in African Americans
-
批准号:7936333
-
项目类别:
-
资助金额:$49.94万
-
财政年份:2009
-
负责人:THOMAS M COFFMAN
-
依托单位:
Genetic Determinants of Susceptibility to Kidney Disease in African Americans
-
批准号:7820192
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:THOMAS M COFFMAN
-
依托单位:
Angiogenic Signals in Diabetic Complications
-
批准号:7896044
-
项目类别:
-
资助金额:$11.04万
-
财政年份:2009
-
负责人:THOMAS M COFFMAN
-
依托单位:
ANGIOTENSIN RECEPTORS/PROSTAGLANDIN E2-REGIONAL BLOOD FLOW IN MOUSE KIDNEY
-
批准号:7726151
-
项目类别:
-
资助金额:$0.65万
-
财政年份:2008
-
负责人:THOMAS M COFFMAN
-
依托单位:
G-PROTEIN PATHWAYS IN THE KIDNEY TRANSPLANT REJECTION
-
批准号:7486792
-
项目类别:
-
资助金额:$20.84万
-
财政年份:2007
-
负责人:THOMAS M COFFMAN
-
依托单位:
Core A
-
批准号:7509555
-
项目类别:
-
资助金额:$0.79万
-
财政年份:2007
-
负责人:THOMAS M COFFMAN
-
依托单位:
ANGIOTENSIN RECEPTORS/PROSTAGLANDIN E2-REGIONAL BLOOD FLOW IN MOUSE KIDNEY
-
批准号:7601191
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2007
-
负责人:THOMAS M COFFMAN
-
依托单位:
CORE--ANIMAL BREEDING AND SURGICAL FACILITY
-
批准号:7486795
-
项目类别:
-
资助金额:$9.56万
-
财政年份:2007
-
负责人:THOMAS M COFFMAN
-
依托单位:
Angiogenic Signals in Diabetic Complications
-
批准号:7288317
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2006
-
负责人:THOMAS M COFFMAN
-
依托单位:
Angiogenic Signals in Diabetic Complications
-
批准号:7151250
-
项目类别:
-
资助金额:$28.43万
-
财政年份:2006
-
负责人:THOMAS M COFFMAN
-
依托单位:
Angiogenic Signals in Diabetic Complications
-
批准号:7492655
-
项目类别:
-
资助金额:$30.21万
-
财政年份:2006
-
负责人:THOMAS M COFFMAN
-
依托单位:
Angiogenic Signals in Diabetic Complications
-
批准号:7907870
-
项目类别:
-
资助金额:$32.82万
-
财政年份:2006
-
负责人:THOMAS M COFFMAN
-
依托单位:
Angiogenic Signals in Diabetic Complications
-
批准号:7684022
-
项目类别:
-
资助金额:$30.21万
-
财政年份:2006
-
负责人:THOMAS M COFFMAN
-
依托单位:
Duke Training Grant in Nephrology
-
批准号:6950184
-
项目类别:
-
资助金额:$16.88万
-
财政年份:2005
-
负责人:THOMAS M COFFMAN
-
依托单位:
ADMINISTRATIVE CORE
-
批准号:6909161
-
项目类别:
-
资助金额:$1.16万
-
财政年份:2005
-
负责人:THOMAS M COFFMAN
-
依托单位:
海外基金